BlackRock Amends AbbVie Stake, Remains Key Institutional Holder
Ticker: ABBV · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a big chunk of AbbVie, signaling continued institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of AbbVie Inc. common stock as of December 31, 2023. This filing, Amendment No. 10, shows BlackRock continues to be a significant institutional holder of AbbVie shares. This matters to investors because large institutional ownership by firms like BlackRock can signal confidence in the company's long-term prospects and can influence stock stability due to their typically long holding periods.
Why It Matters
This filing confirms BlackRock's continued substantial investment in AbbVie, which can be a positive signal for other investors and contribute to stock stability.
Risk Assessment
Risk Level: low — This filing is routine and indicates stable institutional ownership, posing minimal risk to investors.
Analyst Insight
Investors should note BlackRock's continued significant stake in AbbVie, which suggests institutional confidence. While not a direct buy signal, it provides a layer of stability and validation for current or prospective shareholders.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- AbbVie Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A amendment
- Amendment No: 10 (number) — the specific amendment number for this filing
FAQ
What type of SEC filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10)'.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' and 'Names of reporting persons. BlackRock, Inc.'.
What is the subject company whose securities are being reported?
The subject company is AbbVie Inc., as identified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc.' and 'ABBVIE INC (Name of Issuer)'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023, as explicitly stated in the filing.
Which rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding AbbVie Inc. (ABBV).